These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32905322)

  • 1. Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from four Bavarian University Breast Centres.
    Hester A; Gaß P; Fasching PA; Krämer AK; Ettl J; Diessner J; Wöckel A; Egger T; Stock K; Redlin J; Andraschko M; Harbeck N; Würstlein R
    Geburtshilfe Frauenheilkd; 2020 Sep; 80(9):924-931. PubMed ID: 32905322
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
    Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
    Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer.
    Muñoz C; Tai X; Arias J; Eisen A; Chaudhry M; Gavura S; Chan KKW
    Curr Oncol; 2024 Mar; 31(3):1633-1644. PubMed ID: 38534957
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
    Trojan A; Roth S; Atassi Z; Kiessling M; Zenhaeusern R; Kadvany Y; Schumacher J; Kullak-Ublick GA; Aapro M; Eniu A
    JMIR Cancer; 2024 Apr; 10():e54178. PubMed ID: 38573759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
    Liu T; Liu D; Jin Y; Dong M
    Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
    Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
    JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars.
    Uifălean A; Ilieş M; Nicoară R; Rus LM; Hegheş SC; Iuga CA
    Pharmaceutics; 2018 Sep; 10(4):. PubMed ID: 30257528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center.
    Piezzo M; D'Aniello R; Avallone I; Barba B; Cianniello D; Cocco S; D'Avino A; Di Gioia G; Di Lauro V; Fusco G; Piscitelli R; von Arx C; De Laurentiis M; Maiolino P
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34068626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population.
    Gagliato D; Reinert T; Rocha C; Tavares M; Pimentel S; Fuzita W; Araújo M; Matias D; Aleixo S; França B; Magaton É; Brito N; Cardoso AC; Castilho V
    Oncol Ther; 2024 Jun; ():. PubMed ID: 38836997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars lining up to compete with Herceptin--opportunity knocks.
    Nelson KM; Gallagher PC
    Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
    Cesarec A; Likić R
    Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.
    Hara F; Tajima K; Tanabe K
    Future Oncol; 2019 Apr; 15(12):1353-1361. PubMed ID: 30767568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of the trastuzumab biosimilar CT-P6.
    Jeong SA; Choi JM; Park JM; Lee JY; Lee SJ; Lee SY; Lee SY; Park YA; Jeong HJ; Song YC; Kim SH; Chang SJ
    Expert Opin Biol Ther; 2019 Oct; 19(10):1085-1095. PubMed ID: 30541352
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China.
    Wu Q; Lian Z; Wang X; Cheng H; Sun J; Yu H; Zhang G; Wu F; Liu J; Chen C
    Front Pharmacol; 2022; 13():1044798. PubMed ID: 36712662
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.